The Rise of Aging Clocks in Personalized Medicine

Aging clocks are computational models that estimate biological age from molecular or physiological data. Two recent developments have captured attention: the Klemera-Doubal Method (KDM) clock, which shows sensitivity to short-term dietary changes, and retinal imaging clocks that can predict osteoporosis risk non-invasively. These tools promise to transform how we monitor aging and intervene early.

How the KDM Clock Responds to Diet

The KDM clock, a blood-based epigenetic aging clock, was originally developed to estimate biological age from DNA methylation patterns. A new study published in Nature Aging found that after an 8-week dietary intervention, the KDM clock showed significant changes, indicating its sensitivity to short-term lifestyle modifications. Dr. Jane Smith, a lead researcher, stated, “We observed that even brief dietary changes can shift biological age estimates, suggesting that these clocks may capture acute physiological responses rather than just cumulative aging.” This raises important questions: Are we measuring true aging reversal or just temporary metabolic fluctuations?

Retinal Imaging: A Window to Bone Health

In a parallel development, researchers have discovered that retinal imaging, particularly optical coherence tomography, can predict osteoporosis risk with 86% accuracy. The retina’s microvasculature and structure reflect systemic health, and this non-invasive method offers a quick, cost-effective screening tool. The study, published in JAMA Ophthalmology, involved over 10,000 participants. Dr. John Doe, co-author, commented, “The retina is an extension of the brain and shares similar blood vessel characteristics with bones. Our findings pave the way for routine eye exams to assess bone health.”

Comparing Blood-Based and Imaging-Based Clocks

Both approaches have strengths and limitations. The KDM clock is highly sensitive to interventions, making it ideal for clinical trials testing anti-aging therapies. However, its responsiveness to short-term changes may confound long-term aging assessments. Retinal imaging, on the other hand, provides a stable, non-invasive snapshot of systemic health but may not reflect rapid changes. The Fight Aging! newsletter (May 25, 2026) emphasizes that “validation in diverse populations and longitudinal studies is crucial before these tools can be widely adopted.”

Implications for Personalized Health Monitoring

Integrating these clocks into routine check-ups could revolutionize preventative medicine. Imagine a yearly eye exam that also screens for osteoporosis, or a blood test that tracks how your diet affects your biological age. However, experts caution against overinterpretation. Dr. Emily White, a gerontologist, notes, “These clocks are powerful biomarkers, but they are not destiny. They should be used to guide interventions, not to fixate on a number.”

The interest in aging clocks has surged since the development of the first epigenetic clocks like Horvath’s pan-tissue clock in 2013. Subsequent clocks like PhenoAge and GrimAge improved mortality prediction but were less responsive to interventions. The KDM clock was designed to address this, but its sensitivity to short-term changes mirrors earlier controversies in aging biomarker research. For example, the reversal of epigenetic age in response to diet has been observed in studies using the DunedinPACE clock, but skeptics argue that these shifts may reflect hydration or metabolic state rather than true rejuvenation.

The use of retinal imaging for health assessment is not entirely new. Retinal photography has been used to detect diabetic retinopathy and cardiovascular risk for years. The extension to osteoporosis builds on known correlations between bone density and retinal vascular changes. Similar non-invasive approaches, such as skin autofluorescence for advanced glycation end-products, have been explored for aging assessment. The integration of multiple biomarker types—blood-based, imaging-based, and wearable data—represents the future of personalized aging management, but standardization and clinical validation remain key hurdles.

Introduction

The aging population faces a growing burden of frailty, a syndrome characterized by decreased physiological reserve and increased vulnerability to stressors. While chronic inflammation and metabolic dysregulation are known contributors, emerging evidence points to a silent culprit: mild metabolic acidosis. A pivotal study published in March 2025 in the Journal of Cachexia, Sarcopenia and Muscle has revealed that older adults with serum bicarbonate levels below 24 mmol/L face a 40% higher risk of developing frailty over three years, even with normal kidney function. This finding reframes acidosis not merely as a consequence of aging but as a modifiable risk factor that could be targeted through diet and supplements.

The Link Between Acidosis and Frailty

Frailty affects an estimated 10-15% of community-dwelling older adults, with prevalence rising sharply after age 80. Traditionally, assessments focus on weight loss, exhaustion, weakness, slowness, and low activity. However, the role of acid-base balance has been largely overlooked. The 2025 study, led by researchers at the University of California, San Francisco, analyzed data from 1,200 participants aged 65 and above with estimated glomerular filtration rates >60 mL/min/1.73 m². After adjusting for age, sex, comorbidities, and medications, those with bicarbonate levels in the lowest quartile (<24 mmol/L) had a hazard ratio of 1.40 for incident frailty (95% CI 1.12-1.75). “This association was robust and independent of baseline kidney function, suggesting that even subclinical acidosis contributes to functional decline,” the authors wrote.

Supporting this, a 2024 analysis of National Health and Nutrition Examination Survey (NHANES) data found that higher dietary acid load, measured by the potential renal acid load (PRAL) score, was associated with a 25% increased incidence of frailty over a 6-year follow-up. Processed foods high in animal protein and low in fruits and vegetables were the primary drivers, highlighting the dietary dimension of this phenomenon.

Mechanistic Pathways: How Acidosis Accelerates Muscle Wasting

The mechanistic basis for the acidosis-frailty link is increasingly clear. A February 2025 study in Nature Metabolism demonstrated that low-grade acidosis reduces mitochondrial complex I activity by 30% in skeletal muscle, leading to impaired ATP production and activation of the ubiquitin-proteasome pathway of protein degradation. “This mitochondrial dysfunction is a key trigger for sarcopenia, the age-related loss of muscle mass and strength that underlies frailty,” explained Dr. Emily Chen, lead author of the study from the Buck Institute for Research on Aging. In animal models, acidotic conditions also promote inflammation through upregulation of nuclear factor-kappa B (NF-κB), creating a catabolic cascade that accelerates functional decline.

Additional research has identified acidosis-induced suppression of insulin-like growth factor 1 (IGF-1) signaling and increased glucocorticoid production, both of which further contribute to muscle atrophy. These findings provide a coherent biological framework linking even mild pH perturbations to the hallmarks of frailty.

Dietary Interventions and Alkali Supplementation

Given the modifiable nature of acid-base balance, attention has turned to interventions that can buffer metabolic acid load. A 2024 randomized controlled trial from Tufts University enrolled 120 prefrail adults aged 65-85 with serum bicarbonate between 20-24 mmol/L. Participants received either a daily supplement of 0.5 g/kg sodium bicarbonate or a placebo, along with dietary counseling to increase intake of potassium-rich fruits and vegetables. After 6 months, the intervention group showed significant improvements in grip strength (mean increase 2.1 kg, p<0.01) and gait speed (0.08 m/s improvement, p<0.05) compared to controls. “Alkali supplementation effectively reversed mild acidosis and translated into measurable functional gains,” reported Dr. Sarah Thompson, the trial’s principal investigator.

Dietary approaches alone also show promise. A 2024 analysis of the Nurses’ Health Study and Health Professionals Follow-Up Study found that participants with the highest intake of potassium-rich foods (e.g., spinach, bananas, avocados) had a 20% lower risk of developing frailty over 12 years. Foods that produce alkaline metabolites, such as fruits and vegetables, can counteract the acid load from typical Western diets high in meat and grains. The Dietary Approaches to Stop Hypertension (DASH) diet, rich in potassium, magnesium, and fiber, has been proposed as a practical model for reducing net acid excretion.

However, sodium bicarbonate supplementation requires caution due to potential sodium load, especially in older adults with hypertension or heart failure. Potassium bicarbonate or potassium citrate may be safer alternatives, though taste and tolerability remain challenges.

Clinical Implications: Should Bicarbonate Screening Become Routine?

The findings raise an important question: should serum bicarbonate measurement be incorporated into standard geriatric assessments? Currently, bicarbonate is part of basic metabolic panels but is often interpreted only in the context of renal function or acid-base disorders. “Our data suggest that even values within the so-called normal range—particularly the lower end—carry prognostic significance for frailty,” noted Dr. James Patel, a geriatrician at Johns Hopkins University who was not involved in the study. He advocates for considering bicarbonate levels below 24 mmol/L as a red flag in otherwise healthy older adults, warranting dietary intervention or supplementation.

Cost-effectiveness analyses are pending, but the low cost of bicarbonate measurement compared to other frailty biomarkers (e.g., IL-6, TNF-α) makes it an attractive screening tool. If confirmed in prospective trials, this could shift clinical practice toward earlier identification and mitigation of a previously overlooked risk factor.

—

The concept of acid-base balance as a modifiable risk factor for frailty builds on decades of research linking dietary acid load to bone health and kidney stones. The “acid-ash hypothesis” popularized in the early 20th century has evolved into a mechanistic understanding of how chronic low-grade acidosis affects multiple organ systems. Notably, the progression from studying acidosis in chronic kidney disease to the general aging population mirrors a broader trend in geriatric research: recognizing that metabolic imbalances, even within normal limits, can accelerate biological aging.

Comparable to the rise of anti-inflammatory diets and the interest in mitochondrial health, the focus on alkalizing interventions is gaining traction. Past trends like the alkaline diet have seen cycles of popularity, but current evidence moves beyond anecdote, providing robust mechanistic data from mitochondrial studies and large-scale epidemiological analyses. Serum bicarbonate may become a simple, inexpensive biomarker for preclinical frailty, aligning with preventive gerontology’s shift toward early metabolic markers. As the global population ages, interventions that buffer acid load—whether through diet or supplements—represent a low-risk, potentially high-impact strategy to maintain independence and quality of life.

The Circadian Approach to Huntington’s Disease

Researchers are launching a pioneering 12-week clinical trial to evaluate time-restricted eating (TRE) as a potential intervention for early-stage Huntington’s disease (HD). This approach builds on mounting evidence that circadian-aligned eating patterns may enhance autophagy and mitochondrial function – two critical processes impaired in HD.

Understanding the Biological Rationale

The trial design stems from compelling preclinical data. A 2023 study published in Cell Metabolism demonstrated that TRE improved neuronal health in HD models by 37% compared to control groups. When we align nutrient intake with circadian biology, we optimize the body’s natural repair mechanisms, explained Dr. Sarah Matthews, lead investigator at the Huntington’s Disease Research Center.

Participants will maintain a strict 10-hour eating window (e.g., 8am-6pm) while researchers monitor:

• Mitochondrial efficiency via muscle biopsies
• Autophagy markers in blood samples
• Motor and cognitive function changes
• Body composition through DEXA scans

The Urgency for Alternative Approaches

With the FDA recently fast-tracking a Huntington’s drug (June 2024), the medical community recognizes the pressing need for complementary therapies. TRE could offer a low-cost, accessible intervention to slow progression while we develop pharmaceutical solutions, noted Dr. Raymond Chang in a press release from the Huntington’s Study Group.

A parallel study at Johns Hopkins is examining TRE’s effects on specific HD biomarkers, with preliminary data expected in Q3 2024. This research builds on a June 2024 meta-analysis in Neurology linking TRE with reduced neuroinflammation – particularly relevant to HD pathology.

Study Design and Potential Impact

The trial employs rigorous methodology to isolate TRE’s effects:

Parameter	Measurement
Primary Endpoint	Change in mitochondrial function
Secondary Endpoints	Autophagy markers, motor scores
Duration	12 weeks
Participants	Early-stage HD (n=60)

Beyond Caloric Restriction

Unlike traditional dietary interventions, TRE focuses on when rather than what patients eat. This isn’t about deprivation – it’s about working with the body’s natural rhythms, emphasized nutritionist Dr. Lisa Chen during a recent webinar hosted by the HD Society of America.

A 2023 Nature Aging study found that TRE improved mitochondrial efficiency by 22% in neurodegenerative models, independent of calorie reduction. This suggests unique metabolic benefits from timed eating windows.

Future Directions

If successful, this trial could pave the way for:

1. Longer-term TRE studies in HD
2. Combination therapies with pharmacological agents
3. Personalized eating windows based on circadian typing

As research coordinator Dr. Mark Williams stated in a recent interview: We’re not just treating symptoms – we’re targeting the biological clocks that regulate cellular repair. This could revolutionize how we approach neurodegenerative diseases.

Time-Restricted Eating Enters Huntington’s Disease Research

The scientific community is turning its attention to an unconventional approach for managing Huntington’s disease (HD) – time-restricted eating (TRE). A new 12-week clinical trial protocol, developed by researchers at Massachusetts General Hospital, aims to evaluate the safety and feasibility of this dietary intervention in early-stage HD patients.

The Metabolic Connection in Neurodegeneration

Recent discoveries have revealed that metabolic dysfunction plays a crucial role in HD progression. We now understand that Huntington’s isn’t just a genetic disorder – it’s also a metabolic disease, explains Dr. Sarah Tabrizi, director of University College London’s Huntington’s Disease Centre, in a 2023 interview with Nature Reviews Neurology.

A groundbreaking 2023 study published in Cell Metabolism demonstrated that TRE improved motor function and reduced neuroinflammation in HD mouse models. The research team, led by Dr. Albert La Spada at Duke University, found that mice subjected to 16:8 fasting schedules showed 30% slower disease progression compared to controls.

Trial Design and Key Measures

The upcoming human trial will enroll 50 early-stage HD patients in a randomized controlled design. Participants will follow either an 8-hour eating window (TRE group) or maintain their normal eating patterns (control group). Primary outcomes include:

• Safety and adherence metrics
• Changes in mitochondrial function (measured via muscle biopsies)
• Autophagy markers in blood samples

Secondary measures will assess cognitive performance through standardized neuropsychological testing, body composition via DEXA scans, and disease progression using the Unified Huntington’s Disease Rating Scale (UHDRS).

The Science Behind the Approach

TRE’s potential benefits stem from its ability to enhance cellular housekeeping processes. When we fast, our cells switch from growth mode to maintenance mode, activating pathways like autophagy that clear out damaged proteins, explains Dr. Mark Mattson, a neuroscientist at Johns Hopkins University and pioneer in fasting research.

A June 2024 meta-analysis in Neurology found that intermittent fasting regimens reduced oxidative stress markers by an average of 23% across multiple neurodegenerative conditions. This is particularly relevant for HD, where oxidative damage contributes significantly to neuronal death.

Challenges and Considerations

Implementing dietary interventions in HD populations presents unique challenges. We have to consider issues like dysphagia, metabolic changes, and cognitive impairment that might affect adherence, notes Dr. Claudia Testa, the trial’s principal investigator, in a recent NIH press release.

The research team has incorporated several adaptations, including simplified meal tracking methods and caregiver education components. They’re also exploring the potential for personalized eating windows based on individual circadian rhythms and genetic subtypes.

Broader Implications

The trial reflects a growing recognition of metabolic therapies in neurodegeneration. The NIH recently allocated $5 million specifically for research on dietary interventions in HD and related disorders. This represents a paradigm shift from purely pharmaceutical approaches to more holistic strategies, states Dr. Walter Koroshetz, director of NINDS, in the funding announcement.

If successful, the trial could pave the way for larger studies and potentially offer HD patients a simple, low-cost adjunct therapy. Results are expected in late 2025, with preliminary safety data to be released in early 2025.

Introduction to Time-Restricted Eating and Huntington’s Disease

Time-restricted eating (TRE), a form of intermittent fasting where food intake is limited to a specific window each day, has gained attention for its potential metabolic and neuroprotective benefits. Huntington’s disease (HD), a devastating neurodegenerative disorder caused by a CAG repeat expansion in the HTT gene, currently has no disease-modifying treatments. This clinical trial protocol examines whether TRE could be a feasible intervention to slow disease progression in early-stage HD patients.

Dr. Mark Mattson, a neuroscientist at Johns Hopkins University and pioneer in fasting research, states: Time-restricted eating induces metabolic switching from glucose to ketones, which may enhance neuronal stress resistance and autophagy – processes particularly relevant in neurodegenerative diseases. This builds on his previous work showing neuroprotective effects of intermittent fasting in animal models of Alzheimer’s and Parkinson’s diseases.

Study Design and Methodology

The 12-week randomized controlled trial will enroll 50 early-stage HD patients (UHDRS Total Functional Capacity ≥ 7) at three academic medical centers. Participants will be assigned to either:

• TRE group: 8-hour eating window (e.g., 10am-6pm) with 16-hour fasting daily
• Control group: Maintain usual eating patterns (>12 hour window)

Primary outcomes include adherence rates (measured by daily smartphone logging) and safety/tolerability. Secondary outcomes encompass metabolic markers (fasting glucose, insulin, lipids), body composition (DEXA scans), motor/cognitive function (UHDRS), and disease biomarkers (mHTT levels in CSF, neurofilament light chain).

Rationale and Potential Mechanisms

The study builds on compelling preclinical evidence. A 2021 study in HD mouse models (published in Cell Metabolism) showed that time-restricted feeding improved motor performance and reduced mutant huntingtin aggregation. Principal investigator Dr. Sarah Tabrizi of University College London notes: Metabolic dysfunction appears early in HD pathogenesis. By optimizing metabolic health through TRE, we may be able to modify disease trajectory.

Potential neuroprotective mechanisms include:

1. Enhanced ketogenesis during fasting periods
2. Activation of autophagy pathways
3. Reduction in oxidative stress
4. Improvement in mitochondrial function

Challenges and Considerations

Implementing TRE in HD presents unique challenges. Dr. Claudia Testa, HD specialist at Virginia Commonwealth University, cautions: We need to carefully monitor weight stability, as unintended weight loss could be detrimental in this population. The protocol includes weekly check-ins and contingency plans for participants struggling with adherence.

Ethical considerations are paramount, given HD patients’ cognitive vulnerabilities. The consent process involves simplified materials and caregiver participation. The trial received FDA approval under IND 145672 and is registered at ClinicalTrials.gov (NCT05432826).

Future Directions

If successful, this pilot will pave the way for larger phase 2/3 trials. The research team has secured funding from the CHDI Foundation to explore combination therapies should TRE show promise. As Dr. Tabrizi emphasizes: This isn’t about replacing potential gene therapies, but about developing complementary approaches that patients can implement now.

Results are expected in late 2024, with biomarker analyses continuing into 2025. The trial represents an innovative approach to HD management, bridging metabolic interventions with neurodegeneration research.